Biofrontera AG
0DOL.L
0DOL.LBiofrontera AG
London Stock Exchange1.17
EUR
-1.22
(-50.97%)
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Ms. Pilar de la Huerta Martinez
- Full Time Employees
- 88
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- Address
- Hemmelrather Weg 201 Leverkusen Germany 51377
- IPO Date
- Apr 21, 2023
- Website
- biofrontera.com
- Similar Companies
- Business
- Biofrontera AG, a biopharmaceutical company, engages in the research, development, and marketing of dermatological products. Its products include Ameluz and BF-RhodoLED lamp for the treatment of mild and moderate actinic keratoses on the face and scalp, field cancerization, and fatal squamous cell carcinoma. The company also develops RhodoLED XL for the treatment of multiple interspersed lesions; Belixos, a modern active cosmetic product for irritated and sensitive skin; and Xepi for the treatment of antibiotic-resistant bacteria. It offers its products primarily in the United States, Europe, and Israel. The company has a collaboration and partnership agreement with Maruho Co., Ltd. Biofrontera AG was founded in 1997 and is headquartered in Leverkusen, Germany.